drugset / Trial / NCT06959550
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Phase 2
Recruiting
90 enrolled
M.D. Anderson Cancer Center
Akesobio Australia Pty Ltd · collabSummit Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2028-07-01
- Completion
- 2030-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |